MTOR and cancer: The authors were able to demonstrate that the combination of vorinostat and fluvastatin enhanced the vorinostat-induced histone acetylation, suppressed the vorinostat-activated mTOR pathway via pivotal fluvastatin-related AMPK activation, thus resulting in renal anti-cancer effect in vitro (human renal cancer cells ACHN, A498, murine renal cancer Renca) and in vivo (Renca mouse model) via apoptosis induction.